Curbing The Drug Marketers

How a clampdown on pitching drugs for unapproved uses is changing the way Big Pharma operates

Empathizing with the drug industry may be tough these days, especially if you just emptied your wallet to pay for your prescription or rode a Greyhound to Canada to buy the same medicine for less. But just for a moment, put yourself in the shoes of pharmaceutical executives who last week attended a conference in Boston on the latest practice to tarnish their trade: the sale and illegal marketing of drugs for "off label" uses not approved by the FDA. "Rarely has a conference been more timely," warned James Dillon, a partner at Foley Hoag, the Boston-based law firm that sponsored...

Want the full story?

Subscribe Now


Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!